Regeneron Pharmaceuticals

REGN-COV2 binding SARS-CoV-2 spike protein

Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development of pharmaceutical drugs. The company was founded in 1988 by Leonard S. Schleifer and George D. Yancopoulos. Regeneron Pharmaceuticals is headquartered in Tarrytown, New York and is listed on the NASDAQ stock exchange.

History

Regeneron Pharmaceuticals was established in 1988 by Leonard S. Schleifer, a neurologist and professor at the Cornell University Medical College, and George D. Yancopoulos, a scientist specializing in molecular immunology. The company initially focused on neurotrophic factors and their regenerative capabilities, hence the name "Regeneron".

Products and Research

Regeneron Pharmaceuticals has developed several FDA-approved drugs, including Eylea, Praluent, and Dupixent. The company is also known for its VelociSuite technology, which accelerates the development of new therapies.

Eylea, also known as aflibercept, is used for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Praluent, also known as alirocumab, is a monoclonal antibody designed to lower LDL cholesterol.

Dupixent, also known as dupilumab, is used for the treatment of people aged 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

COVID-19 Response

In response to the COVID-19 pandemic, Regeneron Pharmaceuticals developed an antibody cocktail, known as REGN-COV2, which was granted Emergency Use Authorization by the FDA in November 2020.

See Also

• Biotechnology
• Pharmaceutical industry in the United States
• List of pharmaceutical companies

   This article is a pharmacology-related stub. You can help WikiMD by expanding it!

   This article is a medical stub. You can help WikiMD by expanding it!